|Bid||0.00 x 1000|
|Ask||119.88 x 800|
|Day's Range||118.00 - 120.26|
|52 Week Range||78.90 - 130.20|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||39.77|
|Earnings Date||Feb 12, 2020 - Feb 17, 2020|
|Forward Dividend & Yield||0.66 (0.55%)|
|1y Target Est||137.00|
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
The addition of ZNLabs expands Zoetis’ reference laboratory capabilities in the U.S.
Wall Street has high hopes for the alternative-meat industry. If the world does end up eating less animal-based protein in the future, other industries—besides just meat producers—will be affected.
The charts of IDEXX Laboratories and Zoetis have weakened recently, and while the Westminster Dog Show is not for a few more months, it looks like these stocks could be going to the dogs. In this daily bar chart of IDXX, below, we can see that prices traded sideways since June with buyers showing up around $260 until today.
Animal-health giant Zoetis topped earnings forecasts Thursday, but Zoetis stock dipped a fraction on in-line sales and narrowed 2019 guidance. Livestock sales continued to flounder.
Helped by a double-digit increase in its pet business, Zoetis reported third-quarter earnings that handily beat Wall Street expectations.
Zoetis (ZTS) delivered earnings and revenue surprises of 5.62% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Inc. shares rose 2.9% in premarket trade Wednesday, after the animal health company beat estimates for the third quarter. Parsippany, N.J.-based Zoetis said it had net income of $433 million. or 90 cents a share, n the quarter, up from $347 million, or 71 cents a share, in the year-earlier period. Adjusted per-share earnings came to 94 cents, ahead of the 88 cents FactSet consensus. Revenue rose 7% to $1.584 billion from $1.480 billion, also ahead of the FactSet consensus of $1.577 billion. "Our companion animal portfolio is once again the main driver of our results, growing 23% operationally based on strong sales of our parasiticide products, our key dermatology portfolio, and diagnostic revenue from the Abaxis acquisition," Chief Executive Joan Ramon Alaix said in a statement. "Livestock sales declined 4% operationally due to lower product sales in cattle, swine and fish, which were partially offset by growth in poultry." The company is now expecting full-year revenue of $6.200 billion to $6.250 billion and adjusted EPS of $3.57 to $3.62. The FactSet consensus is for revenue of $6.239 billion and EPS of $3.57. Shares have gained 42% in 2019, while the S&P 500 has gained 23%.
On Thursday, November 7, Zoetis (NYSE: ZTS ) will release its latest earnings report. Check out Benzinga's preview to understand the implications. Earnings and Revenue Wall Street expects EPS of 88 cents ...
"The end of the year can still be a good year for us," said Francine Lai on Yahoo Finance's "The Final Round." The Investment Advisor Representative at Gerber Kawasaki Wealth and Investment Management believes that while the economy may be slowing down, it's still growing overall - and will only grow more with the results of consumer spending from shopping for the holidays.